Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan 75 mg versus placebo for inoperable or persistent/recurrent CTEPH
MOH_2020-11-03_009083Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Macitentan with Placebo (2 arms). Started Oct 2020; status: completed.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on MOH_2020-11-03_009083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-03_009083.